MTSS1在胆管癌组织中的表达及其与预后关系

Expression of MTSS1 in cholangiocarcinoma tissue and its relationship with the prognosis of patients

    摘要
  • 摘要:
    目的 探讨MTSS1在胆管癌组织中的表达及其与预后关系。
    方法 收集2003年1月至2005年12月第二军医大学东方肝胆外科医院手术切除的49例肝门部胆管癌患者的胆管标本，构建肝门部胆管癌组织芯片和10例对应癌旁正常胆管上皮的组织芯片，免疫组织化学染色方法检测MTSS1的表达情况；并以脂质体法转染胆管癌细胞株RBE，Western blot法检查MTSS1蛋白表达情况，MTT法检查RBE细胞增殖能力。患者采用门诊和电话随访，随访时间截至2012年5月。计量资料采用t检验，计数资料采用X2检验，Kaplan-Meier法绘制生存曲线，单因素生存分析采用Log-rank检验，多因素生存分析采用COX回归模型。
    结果 免疫组织化学染色结果显示：MTSS1在癌旁正常胆管上皮组织中的表达率为10/10，而在胆管癌组织中的表达率仅为59.2%(29/49)。转染MTSS1的胆管癌细胞增殖比率为1.55±0.05，低于没有转染MTSS1的胆管癌细胞的2.32±0.08(t=4.454，P<0.05)。性别、年龄、TNM分期、T分期、组织分化、神经侵犯、肿瘤直径等不影响MTSS1的阳性表达(X2=0.211，3.471，0.507，0.507，0.368，0.882，0.660， P<0.05)，而淋巴结转移则影响MTSS1的阳性表达(X2=10.436，P<0.05)。所有患者随访1～59个月，中位随访时间16个月。MTSS1阳性表达患者中位无瘤生存时间为17.9个月，MTSS1阴性表达患者为11.3个月，两者比较，差异无统计学意义(Log-rank值=3.707，P>0.05)。MTSS1阳性表达患者中位生存时间为34.9个月，而MTSS1阴性表达患者仅有18.7个月，两者比较，差异有统计学意义(Log-rank值=5.671，P<0.05)。多因素生存分析结果显示：MTSS1表达不是影响患者预后的独立危险因素(X2=0.406，P>0.05)。
    结论 MTSS1在胆管癌原发灶中表达下降，与淋巴结转移呈负相关，是判断胆管癌患者预后的重要指标。

     

    Abstract:
    Objective To investigate the expression of MTSS1 in cholangiocarcinoma tissue and its relationship with the prognosis of patients.
    Method The specimens of bile duct of 49 patients with hilar cholangiocarcinoma who received surgical excision at the Eastern Hepatobiliary Surgery Hospital from January 2003 to December 2005 were collected. Tissue microarrays of the 49 samples of hilar cholangiocarcinomas and the 10 samples of adjancent normal bile duct epithelial tissue were constructed. The expression of MTSS1 was detected by the immunohistochemical staining. The pcDNA3.1MTSS1 was transferred into the RBE cells and the abilities of proliferation of REB cells were measured by MTT assay. The patients were followed up via out patient examination and telephone till May 2012. The measurement data were analyzed using the t test, and the count data were analyzed using the chi square test,the survival curve was drawn by the Kaplan-Meier method,the survival was analyzed using the Logrank test, and multivariate analysis was done using the COX regression model.
    Results The results of immunohistochemical staining showed that the expression rate of MTSS1 was 10/10 in the adjacent normal epithelial tissue of bile duct, while 59.2%(29/49) in the cholangiocarcinoma tissues.The proliferative rate of cholangiocarcinoma cells transfected with MTSS1 was 1.55±0.05, which was significantly lower than 2.32±0.08 of cholangiocarcinoma cells without transfection of MTSS1 (t=4.454, P<0.05). Gender, age,TNM stage,T stage, differentiation, neural invasion and diameter of tumor did not influence the expression of MTSS1 (X2=0.211, 3.471, 0.507, 0.507, 0.368, 0.882, 0.660, P<0.05), while lymph node metastasis influenced the expression of MTSS1 (X2=10.436, P<0.05). All the patients were followed up for 1-59 months, and the median time for followup was 16 months. The median tumorfree survival time was 17.9 months in patients with
    positive expression of MTSS1, and 11.3 months of patients with negative expression of MTSS1, with no significant difference (Log-rank value=3.707, P>0.05). The median survival time was 34.9 months in patients with positive expression of MTSS1, which was significantly longer than 18.7 months of patients with negative expression of MTSS1 (Log-rank value=5.671, P<0.05). Multivariate analysis showed that MTSS1 was not the independent risk factor influencing the prognosis of patients (X2=0.406, P>0.05).
    Conclusions The expression of MTSS1 is decreased in cholangiocarcinoma tissue, which negatively correlates with lymph node metastasis. MTSS1 could be used as a biomarker in predicting the prognosis of patients with cholangiocarcinoma.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回